Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel Free AIDX Stock Alerts

20/20 Biolabs (AIDX) Competitors

20/20 Biolabs logo
$0.55 +0.03 (+5.86%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$0.56 +0.01 (+1.82%)
As of 08/14/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AIDX vs. MGRX, BMGL, GXAI, NIVF, and IVF

Should you buy 20/20 Biolabs stock or one of its competitors? 20/20 Biolabs's main competitors and comparable companies include Mangoceuticals (MGRX), Basel Medical Group (BMGL), Gaxos.ai (GXAI), NewGenIvf Group (NIVF), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does 20/20 Biolabs compare to Mangoceuticals?

20/20 Biolabs (NASDAQ:AIDX) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

56.7% of Mangoceuticals shares are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by company insiders. Comparatively, 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Mangoceuticals had 2 more articles in the media than 20/20 Biolabs. MarketBeat recorded 5 mentions for Mangoceuticals and 3 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.32 beat Mangoceuticals' score of 0.23 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company Overall Sentiment
20/20 Biolabs Positive
Mangoceuticals Neutral

20/20 Biolabs has higher revenue and earnings than Mangoceuticals. 20/20 Biolabs is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$2.05M3.28-$3.74M-$0.28N/A
Mangoceuticals$315.23K29.10-$20.64M-$1.01N/A

20/20 Biolabs presently has a consensus target price of $5.00, indicating a potential upside of 810.75%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts clearly believe 20/20 Biolabs is more favorable than Mangoceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

20/20 Biolabs has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. 20/20 Biolabs' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
Mangoceuticals -4,794.60%-92.68%-87.43%

Summary

20/20 Biolabs beats Mangoceuticals on 11 of the 15 factors compared between the two stocks.

How does 20/20 Biolabs compare to Basel Medical Group?

20/20 Biolabs (NASDAQ:AIDX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

20/20 Biolabs has higher earnings, but lower revenue than Basel Medical Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$2.05M3.28-$3.74M-$0.28N/A
Basel Medical Group$14.55M0.58-$9.50MN/AN/A

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
Basel Medical Group N/A N/A N/A

In the previous week, Basel Medical Group had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 4 mentions for Basel Medical Group and 3 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.32 beat Basel Medical Group's score of 0.89 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company Overall Sentiment
20/20 Biolabs Positive
Basel Medical Group Positive

20/20 Biolabs presently has a consensus target price of $5.00, indicating a potential upside of 810.75%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts clearly believe 20/20 Biolabs is more favorable than Basel Medical Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Basel Medical Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

20/20 Biolabs beats Basel Medical Group on 6 of the 8 factors compared between the two stocks.

How does 20/20 Biolabs compare to Gaxos.ai?

20/20 Biolabs (NASDAQ:AIDX) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

20/20 Biolabs has higher revenue and earnings than Gaxos.ai. 20/20 Biolabs is trading at a lower price-to-earnings ratio than Gaxos.ai, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$2.05M3.28-$3.74M-$0.28N/A
Gaxos.ai$1.93M3.06-$3.90M-$0.50N/A

20/20 Biolabs has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. 20/20 Biolabs' return on equity of 0.00% beat Gaxos.ai's return on equity.

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
Gaxos.ai -64.81%-38.79%-36.99%

20/20 Biolabs currently has a consensus target price of $5.00, indicating a potential upside of 810.75%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than Gaxos.ai.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Gaxos.ai had 8 more articles in the media than 20/20 Biolabs. MarketBeat recorded 11 mentions for Gaxos.ai and 3 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.32 beat Gaxos.ai's score of 0.88 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company Overall Sentiment
20/20 Biolabs Positive
Gaxos.ai Positive

42.6% of Gaxos.ai shares are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by insiders. Comparatively, 3.2% of Gaxos.ai shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

20/20 Biolabs beats Gaxos.ai on 12 of the 15 factors compared between the two stocks.

How does 20/20 Biolabs compare to NewGenIvf Group?

NewGenIvf Group (NASDAQ:NIVF) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

NewGenIvf Group has higher revenue and earnings than 20/20 Biolabs.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewGenIvf Group$4.73M0.73$9.88MN/AN/A
20/20 Biolabs$2.05M3.28-$3.74M-$0.28N/A

In the previous week, 20/20 Biolabs had 1 more articles in the media than NewGenIvf Group. MarketBeat recorded 3 mentions for 20/20 Biolabs and 2 mentions for NewGenIvf Group. NewGenIvf Group's average media sentiment score of 1.44 beat 20/20 Biolabs' score of 1.32 indicating that NewGenIvf Group is being referred to more favorably in the media.

Company Overall Sentiment
NewGenIvf Group Positive
20/20 Biolabs Positive

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 810.75%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than NewGenIvf Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Company Net Margins Return on Equity Return on Assets
NewGenIvf GroupN/A N/A N/A
20/20 Biolabs N/A N/A N/A

66.2% of NewGenIvf Group shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by company insiders. Comparatively, 29.8% of 20/20 Biolabs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

NewGenIvf Group and 20/20 Biolabs tied by winning 5 of the 10 factors compared between the two stocks.

How does 20/20 Biolabs compare to INVO Fertility?

20/20 Biolabs (NASDAQ:AIDX) and INVO Fertility (NASDAQ:IVF) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

20/20 Biolabs has higher earnings, but lower revenue than INVO Fertility. 20/20 Biolabs is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$2.05M3.28-$3.74M-$0.28N/A
INVO Fertility$6.84M0.33-$25.13M-$352.18N/A

In the previous week, 20/20 Biolabs had 1 more articles in the media than INVO Fertility. MarketBeat recorded 3 mentions for 20/20 Biolabs and 2 mentions for INVO Fertility. 20/20 Biolabs' average media sentiment score of 1.32 beat INVO Fertility's score of 0.46 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company Overall Sentiment
20/20 Biolabs Positive
INVO Fertility Neutral

20/20 Biolabs currently has a consensus price target of $5.00, indicating a potential upside of 810.75%. INVO Fertility has a consensus price target of $20.00, indicating a potential upside of 1,958.46%. Given INVO Fertility's stronger consensus rating and higher possible upside, analysts plainly believe INVO Fertility is more favorable than 20/20 Biolabs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

20/20 Biolabs has a net margin of 0.00% compared to INVO Fertility's net margin of -183.75%. 20/20 Biolabs' return on equity of 0.00% beat INVO Fertility's return on equity.

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
INVO Fertility -183.75%-420.62%-45.21%

12.0% of INVO Fertility shares are owned by institutional investors. 29.8% of 20/20 Biolabs shares are owned by company insiders. Comparatively, 0.4% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

20/20 Biolabs beats INVO Fertility on 10 of the 16 factors compared between the two stocks.

Get 20/20 Biolabs News Delivered to You Automatically

Sign up to receive the latest news and ratings for AIDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AIDX vs. The Competition

Export
Metric20/20 BiolabsHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$6.73M$9.87B$7.03B$13.07B
Dividend YieldN/A2.54%2.57%10.64%
P/E Ratio-1.9635.17271.5425.40
Price / Sales3.284.87673.88125.76
Price / CashN/A124.2475.7053.27
Price / BookN/A3.9412.926.21
Net Income-$3.74M$309.96M$3.45B$347.71M
7 Day Performance20.61%0.09%1.16%1.08%
1 Month Performance3.62%-0.34%2.17%1.87%
1 Year PerformanceN/A19.48%62.38%20.79%

20/20 Biolabs Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AIDX
20/20 Biolabs
2.7549 of 5 stars		$0.55
+5.9%		$5.00
+810.7%		N/A$6.73M$2.05MN/A14
MGRX
Mangoceuticals
0.655 of 5 stars		$0.56
+14.4%		N/A-67.4%$9.67M$460KN/A3
BMGL
Basel Medical Group
0.9513 of 5 stars		$5.11
-10.4%		N/A-77.2%$7.97M$8.90MN/A36
GXAI
Gaxos.ai
1.3929 of 5 stars		$0.86
+0.6%		N/A-22.8%$6.10M$1.93MN/A3
NIVF
NewGenIvf Group
2.9176 of 5 stars		$0.65
+4.0%		N/A-99.8%$3.87M$4.73MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AIDX) was last updated on 8/16/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
A Dark Day Is Coming to America
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
What is Trump’s decade-long obsession?
No president has moved markets like Trump, adding and erasing trillions in value seemingly at will. Analyst...
Brownstone Research | Sponsoredtc pixel